Cargando…
Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation
The last several decades have witnessed a substantial decrease in the incidence of acute allograft rejection following kidney transplantation, although commensurate improvements in long-term graft function have not been realized. As a result, the primary focus of new immunosuppressive drug developme...
Autores principales: | Gupta, Gaurav, Womer, Karl L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2998809/ https://www.ncbi.nlm.nih.gov/pubmed/21151624 http://dx.doi.org/10.2147/DDDT.S10432 |
Ejemplares similares
-
Combined Immunotherapy With Belatacept and BTLA Overexpression Attenuates Acute Rejection Following Kidney Transplantation
por: Zhang, Hengcheng, et al.
Publicado: (2021) -
Belatacept in renal transplantation—quo vadis?
por: Westhoff, Timm H.
Publicado: (2016) -
Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update
por: Wojciechowski, David, et al.
Publicado: (2012) -
Belatacept for the prophylaxis of organ rejection in kidney transplant patients: an evidence-based review of its place in therapy
por: Hardinger, Karen L, et al.
Publicado: (2016) -
Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants
por: Kumar, Dhiren, et al.
Publicado: (2017)